| Identification | Back Directory | [Name]
CALYCOSIN 7-O-GLUCOSIDE | [CAS]
20633-67-4 | [Synonyms]
CS-2023
CALYCOSIN 7-O-GLUCOSIDE
calycosin-o-glucopyranoside
calycosin-7-O-β-D-glucoside
Calycosin-7-O-b-D-glucoside
Calycosin-7-O-B-D-glycoside
Calycosin-7-O-beta-D-glucoside
Calycosin-7-glucoside 20633-67-4
Calycosin 7-O-Glucoside Standard
Calycosin 7-O-β-D-glucopyranoside
Calycosin-7-O-b-D-glucopyranoside
3',7-Dihydroxy-4'-Methoxyisoflavone-7-beta-D-glucopyranoside
4H-1-Benzopyran-4-one, 7-(β-D-glucopyranosyloxy)-3-(3-hydroxy-4-methoxyphenyl)-
3-(3-hydroxy-4-methoxyphenyl)-7-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one | [Molecular Formula]
C22H22O10 | [MDL Number]
MFCD08061493 | [MOL File]
20633-67-4.mol | [Molecular Weight]
446.4 |
| Chemical Properties | Back Directory | [Melting point ]
220 - 228°C | [Boiling point ]
745.2±60.0 °C(Predicted) | [density ]
1.545 | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
9.48±0.10(Predicted) | [color ]
Pale Beige | [InChIKey]
WACBUPFEGWUGPB-YFUKJJPONA-N | [SMILES]
O=C1C(C2C=CC(OC)=C(O)C=2)=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C12 |&1:18,19,20,22,24,r| |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, soluble in methanol and ethanol, derived from the rhizome of Astragalus membranaceus. | [Uses]
Calycosin 7-O-β-D-glucoside is one of seven constituent in Guanjiekang (GJK) that is formed by five medicinal herbs that is used for the rheumatoid arthritis (RA). | [Definition]
ChEBI: Calycosin-7-O-beta-D-glucoside is a glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage. It is a hydroxyisoflavone, a monosaccharide derivative, a member of 4'-methoxyisoflavones and a 7-hydroxyisoflavones 7-O-beta-D-glucoside. It is functionally related to a calycosin. | [in vivo]
Calycosin-7-O-β-D-glucoside (intraperitoneal injection; 26.8 mg/kg; 14 days) significantly reduces infarct volume, histological damage and BBB permeability in the in vivo MCAO ischemia-reperfusion rat model[1]. | Animal Model: | Middle cerebral artery occlusion (MCAO) male adult Sprague-Daweley rats[1] | | Dosage: | 26.8 mg/kg | | Administration: | Intraperitoneal injection; 26.8 mg/kg; 14 days | | Result: | Exhibited neuroprotective effects in rats. |
|
|
|